July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
The FDA approved subcutaneous isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis US LLC) for multiple myeloma treatment regimens across relapsed, refractory, and newly diagnosed disease settings.
March 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
As researchers continue exploring early-intervention strategies for high-risk smoldering multiple myeloma, understanding the basic pathophysiology of plasma cell disorders (and the targets of emerging...
In this episode, Anil Harrison, MD, speaks with Dharminder Singh, MD, about the evaluation of renal tubular acidosis (RTA) and how to evaluate metabolic alkalosis. The first patient case presentation is a...
Joshua Richter, MD, associate professor of medicine, hematology, and oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, reviews real-world data presented at the SOHO 2022 Annual...